| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1893e58a79a78de604ff4b09e05c578b |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-65 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-05 |
| filingDate |
2018-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c25065800fd097c2206756f438b4eb2f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_70e08abcc9bd35e12ebc5a10e5f1129b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_47193e52323637523ceedb59e2ac3b0c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6986a9e7898e18ebd3f44151c7761a63 |
| publicationDate |
2022-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022289792-A1 |
| titleOfInvention |
Bicyclic peptide ligands specific for epha2 |
| abstract |
The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour). |
| priorityDate |
2017-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |